Dual-release hydrocortisone treatment: glycometabolic profile and health-related quality of life

摘要

Objective Adrenal insufficiency (AI) is a chronic condition associated with increased mortality and morbidity. The treatment of AI in the last years has been object of important changes due to the development of a dual-release preparation of hydrocortisone. It differs from previous therapeutic strategy as it contemplates a once-daily tablet that allows more closely mimicking the physiological circadian cortisol rhythm. The aim of the study was to evaluate the effects of dual-release hydrocortisone treatment on the glycometabolic profile and health-related quality of life of patients with AI. Design and Methods In this clinical open trial, we enrolled ten patients with primary AI (41?±?2.67?years) and nine patients with AI secondary to hypopituitarism (53.2?±?17.7?years). We evaluated the glycometabolic profile before and 3, 6, 9 and 12?months after dual-release hydrocortisone administration. We also evaluated health-related quality of life, estimated by the AddiQol questionnaire. The mean dose administered of dual-release hydrocortisone was 28.33?±?6.68?mg/day. Results One female hypopituitary patient dropped out from the study. After 12?months of treatment, the mean dosage administered of dual-release hydrocortisone was significantly lower ( P ?